Isotopia Molecular Imaging ltd’s Post

On Wednesday, April 24th, the final discussion for one of the largest Kansen voor West II projects took place: FIELD-LAB. Representing Kansen voor West, Jeroen Elzenaar, Ruud van Raak en Tessa de Boer visited Petten to meet with Karlijn van der Schilden, Paula van der Vlies, Angelique de Boer-l'Istelle en Vinod Ramnandanlal. The Kansen voor West II project, named “Advancing Nuclear Medicine, Petten FIELD-LAB,” has resulted in a state-of-the-art GMP production facility. FIELD-LAB contributes to the acceleration of the development of new nuclear medicines. This facility is utilised for the production of promising radioactive materials for the preparation of innovative nuclear medications. FIELD-LAB also ensures the development of the necessary production processes. Significant achievements so far include a sustainable concept of a production system for two promising so-called starting materials and base material for two new therapies for cancer treatment. A tracer is being developed to better select patients for chemotherapy. Additionally, a dozen feasibility studies have been initiated for the product development of industrial parties. #precisionmedicine #healthcareinnovation #medicine #innovation

The European Association of Nuclear Medicine (EANM) and Nuclear Medicine Europe (NMEU) express disappointment over the recent European Parliament vote on the #Pharmaceutical #Regulation and Directive, which did not incorporate their proposed amendments aimed at updating the regulatory framework for #radiopharmaceuticals. Despite the pivotal role #NuclearMedicine plays in modern healthcare, especially in cancer care as recognized by EU initiatives like the SAMIRA Action Plan, the current legislative approach fails to acknowledge the significant advancements in radiopharmaceuticals since 2004. This oversight poses challenges to the industry and clinical sectors, leading to uncertainties and reduced availability of radiopharmaceuticals across Europe. EANM and Nuclear Medicine Europe advocate for a regulatory framework that aligns with the evolving landscape of Nuclear Medicine, emphasizing the need for updated definitions and provisions to support the growth and accessibility of radiopharmaceuticals. They call upon policymakers to reconsider these developments and ensure that the revised legislation reflects the advancements in Nuclear Medicine, ultimately benefiting patients across the EU. Download the full statement : https://lnkd.in/ewenrYx

Should Australia look towards creating a radiopharmaceutical specific reimbursement pathway? As it currently stands there are both MSAC and PBAC avenues but the process is fragmented and poorly understood. The latest MSAC PSD gives clear evidence of this. With so much investment in nuclear medicine globally, is Australia at risk of falling behind? https://lnkd.in/gEg4AJg9

Nuclear Medicine is a medical specialty involving the application of radioactive substances in the diagnosis and treatment of a variety of diseases.   Specialized formulation and dispensing equipment is essential for safe formulation, dispensing, packing and inspection of these products.   PBL’s N-R&D Integrated Formulation & Dispensing “Hot Cell” system featured in this video covers all your needs for safe and efficient production of Nuclear Medicines.   IMAS INGENIOUS MACHINES proudly represents PBL in South Africa. Get in touch with Paul Adams 🇿🇦 or Lyn-Ann Adams of IMAS, or Andrea Gui of PBL, for more information.   #southafrica #pharmaceuticalindustry #pharmaceuticalmanufacturing #injectables #parenterals #nuclearmedicine

Nuclear Medicine Europe is the professional association of companies active in the nuclear medicine field across the world (notwithstanding the "Europe" in its name). Its role in the currently ongoing revolution in the nuclear medicine field with promising new therapeutic options in cancer care in full development, cannot be overestimated. One of the major challenges the industry is facing is putting in place and securing the various supply chains and the logistics they require, not in the least the radioisotope supply. Given my experience in the domain, I would like to strongly advocate to spend money and time on making these supply chains independent from national and international subsidies and control, instead of asking oneself how subsidies and control can stabilise these chains. The ongoing boom in radiopharma offers an opportunity to correct mistakes from the past in which isotope production was left to national labs and heavily subsidized, creating a market which is now incapable of surviving without subsidies. The biggest example is the Mo-99 supply chain, which relies on a handful of ageing reactors throughout the world (>50% of it is coming from 2 reactors in Belgium and the Netherlands). It is vital that radiopharmaceuticals are accepted to have a COGS of 8-12% (compared to the typically much lower COGS of other pharma products) and in that sense allow radioisotope production to become commercially viable and sustainable. Allowing the market dynamics to play its role will improve the quality of service provided by the producers and will create a viable business case for the construction of dedicated isotope production reactors. Even without commercial reactors, assuring a proper margin for the production of these highly technological and life-saving ingredients of radiopharma can be achieved. If the reimbursement of the radioisotope is separated from the reimbursement of the pharmaceutical, the participation of all countries to the isotope production cost, proportional to their use of radiopharma products, will be assured. Today, the taxpayers of a few countries help fund the production of medical radioisotopes for the rest of the world, which is not sustainable... The NMEu will help us to address these and many other issues at a European and even global level, creating a hopeful future for cancer patients !

Nuclear Medicine is a medical specialty involving the application of radioactive substances in the diagnosis and treatment of a variety of diseases.   Specialized formulation and dispensing equipment is essential for safe formulation, dispensing, packing and inspection of these products.   PBL’s N-R&D Integrated Formulation & Dispensing “Hot Cell” system featured in this video covers all your needs for safe and efficient production of Nuclear Medicines.   IMAS INGENIOUS MACHINES proudly represents PBL in South Africa. Get in touch with Paul Adams 🇿🇦 or Lyn-Ann Adams of IMAS, or Andrea Gui of PBL, for more information.   #southafrica #pharmaceuticalindustry #pharmaceuticalmanufacturing #injectables #parenterals #nuclearmedicine

At the heart of every RLS radiopharmacy is a team of dedicated nuclear pharmacists and personnel who take great pride in their work. Their expertise ensures that every order, without exception, is prepared, dispensed and delivered with precision. Our in-house couriers and robust delivery fleet echo this precision, assuring life-saving radiopharmaceuticals arrive where they are needed and when they are needed, without fail. https://rls.bio/ #NuclearPharmacy #Radiopharmacy #nuclearmedicine

Units of Measurement for Radioactive Material Used in Nuclear Medicine and Radiopharmaceutical Manufacturing. #NuclearMedicine #Radiopharmaceuticals #RadiationSafety #HealthcareInnovation #MedicalPhysics

Nuclear Medicine Market worth $9.4 billion by 2028 𝐃𝐨𝐰𝐧𝐥𝐨𝐚𝐝 𝐏𝐃𝐅 𝐁𝐫𝐨𝐜𝐡𝐮𝐫𝐞: https://lnkd.in/dQihBbJM The global #nuclearmedicine market in terms of revenue was estimated to be worth $5.5 billion in 2023 and is poised to reach $9.4 billion by 2028, growing at a CAGR of 11.3% from 2023 to 2028. #radiopharmaceuticals 𝐎𝐩𝐩𝐨𝐫𝐭𝐮𝐧𝐢𝐭𝐲: Use of radiopharmaceuticals in neurological applications GE HealthCare Cardinal Health Curium Pharma Bayer Lantheus Bracco PharmaLogic Holdings Corp. Eczacıbaşı-Monrol Nuclear Products NTP Radioisotopes SOC Ltd. (A SUBSIDIARY OF @SOUTH AFRICAN NUCLEAR ENERGY CORPORATION) Nordion Advanced Accelerator Applications (A Novartis COMPANY) NorthStar Medical Radioisotopes, LLC Eckert & Ziegler AG Siemens Healthineers JUBILANT DRAXIMAGE RADIOPHARMACIES INC. Global Medical Solutions SHINE Technologies Isotopia Molecular Imaging ltd. BWXT Medical Ltd. Institute of Isotopes Co. Ltd. China Isotope & Radiation Corp Yantai Dongcheng Pharmaceutical Group Co., Ltd Cyclopharm IRE ELiT - Radiopharma

The specific activity of a radionuclide refers to the activity per unit mass of a radioactive substance. It is a measure of the amount of radioactivity that is present in a given quantity of a material. The specific activity is usually expressed in units of becquerels per gram (Bq/g) or curies per gram (Ci/g). The activity of a radionuclide is determined by its decay rate, which is characteristic of each radioactive isotope. This decay rate is defined by the half-life of the isotope, which is the time it takes for half of the atoms in a sample to decay. Radionuclides with shorter half-lives have higher specific activities because they decay more rapidly, releasing their radiation in a shorter period of time. The specific activity can be important in various fields, such as in nuclear medicine, where it helps in determining the appropriate dose of a radioactive drug, and in environmental monitoring, where it helps in assessing the level of contamination by radioactive substances. #radiopharmaceuticals #nuclearmedicine